Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update
by Danessa Lincoln · The Markets DailyAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 102,286 shares, a decline of 90.2% from the March 15th total of 1,045,893 shares. Based on an average trading volume of 2,267,481 shares, the short-interest ratio is presently 0.0 days. Currently, 4.5% of the company’s shares are sold short.
Acurx Pharmaceuticals Trading Down 3.0%
Acurx Pharmaceuticals stock traded down $0.08 during mid-day trading on Friday, reaching $2.61. The company had a trading volume of 132,147 shares, compared to its average volume of 2,830,646. Acurx Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $21.00. The company has a market cap of $7.46 million, a P/E ratio of -0.46 and a beta of -1.92. The business has a fifty day simple moving average of $2.93 and a 200 day simple moving average of $3.80.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.70. Research analysts forecast that Acurx Pharmaceuticals will post -0.89 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 28th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $31.00.
Read Our Latest Stock Analysis on Acurx Pharmaceuticals
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ACXP. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals in the second quarter valued at about $551,000. Geode Capital Management LLC bought a new position in shares of Acurx Pharmaceuticals in the 4th quarter worth $31,000. Jane Street Group LLC bought a new position in shares of Acurx Pharmaceuticals in the 4th quarter worth $27,000. Finally, Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals in the 4th quarter valued at $103,000. Institutional investors own 11.53% of the company’s stock.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.
Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).